Benmelstobart plus anlotinib and chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: A phase 2 study

Summary: This phase 2 study investigates first-line benmelstobart plus anlotinib and chemotherapy in human epidermal growth factor receptor 2 (HER2)-negative unresectable locally advanced/metastatic gastric or gastroesophageal junction (G/GEJ) cancer. Twenty-five eligible patients receive benmelstob...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Liangyu Bie, Chen Wei, Suxia Luo, Shuailei Dong, Zhiwei Gu, Yijie Ma, Qingxin Xia, He Zhang, Jing Li, Wenying Deng, Ning Li
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	Elsevier 2025-06-01
Serie:	Cell Reports Medicine
Soggetti:	benmelstobart plus anlotinib and chemotherapy HER2-negative G/GEJ phase 2 study first-line therapy PD-L1 PBIC profile
Accesso online:	http://www.sciencedirect.com/science/article/pii/S2666379125002186
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!